HC Wainwright Forecasts Lower Earnings for Palisade Bio

Palisade Bio, Inc. (NASDAQ:PALI) – Equities researchers at HC Wainwright dropped their FY2026 EPS estimates for shares of Palisade Bio in a note issued to investors on Wednesday, November 11th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($0.24) for the year, down from their prior forecast of ($0.20). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Palisade Bio’s current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Palisade Bio’s Q4 2026 earnings at ($0.07) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.33) EPS.

A number of other research analysts also recently weighed in on PALI. Wall Street Zen downgraded shares of Palisade Bio from a “hold” rating to a “sell” rating in a research report on Saturday, October 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Palisade Bio in a research note on Monday, October 12th. Oppenheimer restated an “outperform” rating on shares of Palisade Bio in a research note on Wednesday, October 21st. Finally, Raymond James Financial initiated coverage on Palisade Bio in a report on Thursday, October 8th. They issued an “outperform” rating and a $6.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Palisade Bio has a consensus rating of “Buy” and an average target price of $9.00.

Palisade Bio Stock Performance

Shares of NASDAQ PALI opened at $1.14 on Friday. The company has a market capitalization of $204.38 million, a PE ratio of -2.38 and a beta of 1.61. The company’s fifty day moving average price is $1.50 and its 200 day moving average price is $1.82. Palisade Bio has a 1 year low of $1.08 and a 1 year high of $2.85.

Palisade Bio (NASDAQ:PALI) last posted its earnings results on Tuesday, November 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.01).

Hedge Funds Weigh In On Palisade Bio

A number of large investors have recently added to or reduced their stakes in the stock. Creek Drive Management Group LLC grew its position in shares of Palisade Bio by 54.5% in the third quarter. Creek Drive Management Group LLC now owns 680,000 shares of the company’s stock valued at $918,000 after purchasing an additional 240,000 shares during the period. ACT Capital Partners L.P. purchased a new stake in shares of Palisade Bio during the third quarter worth about $415,000. China Universal Asset Management Co. Ltd. raised its position in shares of Palisade Bio by 19.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 81,000 shares of the company’s stock worth $117,000 after purchasing an additional 13,110 shares during the last quarter. WINTON GROUP Ltd raised its position in shares of Palisade Bio by 180.2% during the 2nd quarter. WINTON GROUP Ltd now owns 32,227 shares of the company’s stock worth $67,000 after purchasing an additional 20,727 shares during the last quarter. Finally, PCG Wealth Advisors LLC acquired a new position in shares of Palisade Bio during the 2nd quarter worth about $86,000. 11.79% of the stock is currently owned by institutional investors and hedge funds.

Palisade Bio Company Profile

Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions. Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.